WEBULL
WebtradeDownload

Rohto Pharmaceutical (TSE:4527) Stock Grapples With Revenue Growth And Thinner Margins

Simply Wall St · 2d ago

Rohto PharmaceuticalLtd stock has been grinding higher in recent months, yet the real story today sits in the earnings margin squeeze that investors have been slowly pricing in. Net profit margin now sits at 9.4%, compared with 10.6% a year earlier, even as trailing P/E sits around 19.5x and below key peers in Japanese personal products. The market has been willing to pay for the Rohto PharmaceuticalLtd brand and its high quality earnings record. This quarter, however, puts the pressure point clearly on profitability rather than revenue.

Love Rohto PharmaceuticalLtd's brand strength but concerned about the pressure on margins? Take a look at our list of solid balance sheet and fundamentals stocks (40 results).

Q1 2027 Earnings Summary

  • Revenue Q1 2027 vs Q1 2026: ¥91,624 million vs. ¥81,964 million (up about 11.8%)
  • Net Income Q1 2027 vs Q1 2026: ¥10,650 million vs. ¥11,769 million (down about 9.5%)
  • Basic EPS Q1 2027 vs Q1 2026: ¥47.13 vs. ¥52.08 (down about 9.5%)
  • Net Profit Margin Q1 2027 vs Q1 2026: 11.6% vs. 14.4% based on net income excluding extra items and total revenue (margin compression of around 2.8 percentage points)

Prefer clean charts instead of reading another wall of earnings tables and ratios? Get a full visual picture of Rohto PharmaceuticalLtd, including a clear view of its profitability trend and margins, through our company report for Rohto PharmaceuticalLtd.

TSE:4527 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:4527 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Rohto bullish story leans on resilient top line

For a bullish view on Rohto PharmaceuticalLtd, the latest quarter still offers support on the revenue side. Sales reached ¥91,624 million compared with ¥81,964 million a year earlier, which is consistent with the idea of a broad, diversified consumer health franchise that can keep customers coming back. The share price has also risen over the past 7, 30 and 90 days, suggesting investors have not abandoned the defensive consumer healthcare and eye care story despite the pressure on earnings.

Margin pressure keeps the Rohto bear case alive

The bear case focuses on profitability, and the fresh numbers keep that concern very much in play. Net income fell from ¥11,769 million to ¥10,650 million and net profit margin compressed from 14.4% to 11.6%. That runs against the narrative of consistently high quality earnings. Even with a steady share price trend, these results flag that Rohto PharmaceuticalLtd is currently paying for growth with weaker margins. This raises fair questions about cost control and pricing power across key product lines.

Reveal where the surface looks calm but the models start to disagree on Rohto PharmaceuticalLtd's next inflection point by checking what the street is quietly building into FY and beyond through the analyst estimates for Rohto PharmaceuticalLtd.

Stay Ahead With Simply Wall St

If Rohto PharmaceuticalLtd's solid revenue line but tightening margins has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and keep an eye out for a more attractive entry point. Once you are invested, keep your decisions clear with the Portfolio Command Center that cuts through market noise and highlights only the key updates that matter to your holdings. For a broader view on what other investors are seeing in Rohto PharmaceuticalLtd and similar stocks, tap into the collective insight inside the Community. By spotting potential catalysts and risks early, you can focus on staying informed and making decisions with confidence.

Seeking Alternatives Beyond Rohto PharmaceuticalLtd

Fresh stock ideas can move quickly, and the strongest stories often gain momentum before most investors catch them. Scan what is still under the radar for now and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.